• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Operates as a development-stage biopharmaceutical company specializing in the discovery, development and commercialization of prescription pain management products. Its lead product candidate, Entereg, is designed to selectively block the unwanted effects of opioid analgesics on the GI tract.
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
No longer subject to file | 2011-12-19 | 0 | |
|
No longer subject to file | 2011-12-19 | 0 | |
|
No longer subject to file | 2011-12-19 | 0 | |
|
No longer subject to file | 2011-12-19 | 0 | |
|
No longer subject to file | 2011-12-12 | 0 | |
|
WEBSTER STEPHEN W SVP, FINANCE & CFO |
|
No longer subject to file | 2011-12-12 | 0 |
|
LIMONGELLI JOHN M SVP, GENERAL COUNSEL & SECR. |
|
No longer subject to file | 2011-12-12 | 0 |
|
88,378,182 | 2011-12-09 | 0 | |
|
DOUGHERTY MICHAEL R PRESIDENT & CEO |
|
0 | 2011-12-07 | 0 |
|
0 | 2011-12-07 | 0 | |
|
0 | 2011-12-07 | 0 | |
|
0 | 2011-12-07 | 0 | |
|
0 | 2011-12-07 | 0 | |
|
0 | 2011-12-07 | 0 | |
|
0 | 2011-12-07 | 0 | |
|
MAURER GEORGE R SVP, MFG. & PHARM TECHNOLOGIES |
|
0 | 2011-12-07 | 0 |
|
1,391,794 | 2011-12-06 | 0 | |
|
0 | 2011-06-30 | 0 | |
|
SALINAS ELISEO ORESTE SVP R&D & CMO |
|
88,675 | 2010-05-24 | 0 |
|
No longer subject to file | 2009-09-22 | 0 | |
|
6,214,551 | 2008-10-31 | 0 | |
|
HESS THOMAS P VP FINANCE & CFO |
|
6,247 | 2008-05-20 | 0 |
|
MANNING MARTHA E SR.VP, GENERAL COUNSEL & SEC. |
|
11,465 | 2008-05-20 | 0 |
|
JACKSON DAVID SR. VP AND CMO |
|
7,355 | 2008-05-20 | 0 |
|
BARRETT JAMES E SR VP,CSO & PRESIDENT,RESEARCH |
|
160,000 | 2007-01-04 | 0 |
|
15,000 | 2006-05-18 | 0 | |
|
GRAHAM ROGER D JR SVP SALES & MARKETING |
|
40,000 | 2006-01-06 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
